I-Alendronate, imithi enamandla, inikeza ithemba kulabo abasengozini yokulahlekelwa amathambo. Lesi sidakamizwa sidlala indima ebalulekile ekwelapheni nasekuvimbeleni kwamathambo. I-Alendronate isebenza ngokunciphisa ukuwohloka kwamathambo nokusiza ukugcina ukuminyana kwamathambo, okuyenza ibe ngumdlali oyinhloko ekulawuleni impilo yamathambo.
I-Alendronate ingeyesigaba semithi ebizwa ngokuthi ama-bisphosphonates. Lesi sidakamizwa esitholakala kudokotela kuphela sidlala indima ebalulekile ekugcineni impilo yamathambo. Odokotela batusa i-alendronate ukwelapha nokuvimbela i-osteoporosis. I-osteoporosis yisifo esihlobene namathambo esenza amathambo abe nezimbotshana futhi abe brittle, okwandisa ingozi yokuphuka.
Amaphilisi e-Alendronate anokusetshenziswa okuningana okubalulekile ekulawuleni impilo yamathambo, njenge:
Ukusetshenziswa ngendlela efanele kwamaphilisi e-alendronate kubalulekile ekusebenzeni kwawo. Iziguli kufanele ziphuze lo muthi esiswini esingenalutho ngokushesha ngemva kokuvuka ekuseni. Ukulinda okungenani imizuzu engu-30 ngaphambi kokudla ukudla, iziphuzo, noma ezinye izidakamizwa kubalulekile.
I-Alendronate, njenganoma yimuphi umuthi, ingabangela imiphumela emibi ehlukahlukene.
Imiphumela emibi evamile ye-alendronate ihlanganisa:
Imiphumela emibi kakhulu, nakuba ingajwayelekile, idinga ukunakekelwa ngokushesha, okufana nalokhu:
I-Alendronate, umuthi onamandla we-bisphosphonate, ibalulekile ekwelapheni nasekuvimbeleni ukukhumuzeka kwamathambo nezinye izimo ezihlobene namathambo. Lesi sidakamizwa sihlose inqubo yokuvuselela amathambo, ikakhulukazi ekuvimbeleni ukuwohloka kwamathambo nokwandisa ukuminyana kwamathambo.
Indlela eyinhloko yesenzo ihlanganisa ukubophezela kwe-alendronate kumakristalu e-hydroxyapatite (amaminerali akhona ngaphakathi kwesakhiwo samathambo). Le nqubo yokubopha iholela ekwehliseni ukulawulwa kwe-osteoclast-mediated bone rebsorption. Ama-osteoclasts amaseli athile anesibopho sokudiliza izicubu zamathambo. Ngokuvimbela lawa maseli, i-alendronate inciphisa ngempumelelo ukuwohloka kwe-bone matrix.
Eminye yemithi evamile engase ihlanganyele ne-alendronate ihlanganisa:
Umthamo we-Alendronate uyahlukahluka futhi uncike esimweni kanye nezidingo zesiguli.
Ngokwelashwa kwe-postmenopausal osteoporosis, abantu abadala ngokuvamile bathatha amaphilisi e-alendronate angu-70 mg kanye ngesonto noma i-10 mg nsuku zonke.
Umthamo ofanayo uyasebenza emadodeni ane-osteoporosis.
Ukuvimbela i-postmenopausal osteoporosis - Umthamo onconywayo ngu-35 mg ngesonto noma u-5 mg nsuku zonke.
I-Alendronate idlala indima ebalulekile ekulawuleni impilo yamathambo, inikeza ithemba kulabo abasengozini yokukhumuzeka kwamathambo nezinye izimo ezihlobene namathambo. Ikhono layo lokunciphisa ukuwohloka kwamathambo nokwandisa ukuminyana kwamathambo kuba nomthelela omkhulu ekunciphiseni izingozi zokuphuka. Ukuguquguquka kwalo muthi ekwelapheni izifo ezihlukahlukene zamathambo kanye nenketho yawo elula yokuthatha umthamo wamasonto onke kuwenza ube inketho ebalulekile ekulweni nokulahlekelwa kwamathambo.
Ukusetshenziswa okufanele kwe-alendronate, ngaphansi kokuqondisa kukadokotela, kubalulekile ukuze uthole inzuzo enkulu futhi unciphise izingozi ezingaba khona. Iziguli kudingeka zilandele imiyalelo ethile yemithi futhi ziqaphele imiphumela engemihle engase ibe khona. Ngokuhlala unolwazi nokugcina ukuxhumana okuvulekile nethimba labo lokunakekelwa kwezempilo, abantu abasebenzisa i-alendronate bangaqinisa amathambo abo futhi bathuthukise ikhwalithi yabo yonke yokuphila.
Imiphumela emibi evame kakhulu yalo muthi ihlanganisa ubuhlungu besisu, ukushaya kwenhliziyo, ukuqunjelwa, isifo sohudo, kanye indigestion. Abanye abantu bangase bazwe ubuhlungu bamathambo, amalunga, noma imisipha. Ezimweni ezingavamile, i-alendronate ingabangela imiphumela emibi kakhulu, njengokucasuka kwe-esophageal noma izilonda.
I-Alendronate inomphumela ohlala njalo emathanjeni, okuvumela ukuba kube nenketho ye-dosing kanye ngesonto. Lolu hlelo lokudosa luthuthukisa ukusebenziseka kalula kweziguli futhi lungase luthuthukise ukunamathela kuhlelo lokwelapha.
Abantu akufanele baphuze i-alendronate enezinkinga ze-oesophageal, labo abangakwazi ukuhlala baqonde noma ukuma okungenani imizuzu engu-30, abantu abane-hypocalcaemia, noma labo abanezinkinga ezinkulu zezinso. Iziguli ezine-allergies kunoma yiziphi izingxenye zomuthi nazo kufanele zikugweme.
Ubude besikhathi obufanele bokusetshenziswa kwe-alendronate abukamiswa ngokuqinisekile. Kodwa-ke, ochwepheshe abaningi basikisela ukuthi kunengqondo ukuthi abantu abasengcupheni ephansi yokuphuka bacabangele ukuwuyeka umuthi ngemva kweminyaka emi-3 kuya kwemi-5 yokusetshenziswa.
Iziguli kufanele zicabange ukuyeka i-alendronate ngemva kweminyaka emi-3 kuya kwemi-5 uma zisengozini ephansi yokuphuka. Kodwa-ke, lesi sinqumo kufanele ngaso sonke isikhathi senziwe ngokubonisana nodokotela, ozohlola kabusha ingozi yokuphuka kwesiguli ngezikhathi ezithile.
Kube nokukhathazeka mayelana nengozi engaba khona ye-fibrillation ye-atrial ngokusetshenziswa kwe-alendronate. Kodwa-ke, izifundo eziningi zehlulekile ukukhombisa ubudlelwane obuqinile, obukholisayo phakathi kokusetshenziswa kwe-alendronate nezinkinga zenhliziyo. Iziguli ezinomlando we-atrial fibrillation kufanele zixoxe ngalokhu nodokotela wazo ngaphambi kokuqala i-alendronate.
Thatha i-alendronate esiswini esingenalutho into yokuqala ekuseni ngengilazi egcwele yamanzi angenalutho. Hlala umile okungenani imizuzu engama-30 ngemuva kokuphuza umuthi. Ungadli, ungaphuzi lutho ngaphandle kwamanzi, noma uphuze eminye imithi ngalesi sikhathi.
Yebo, kunezinye izindlela ze-alendronate zokwelapha i-osteoporosis. Lokhu kungase kuhlanganise amanye ama-bisphosphonates, i-hormone therapy, i-raloxifene, noma eminye imithi. Ukukhethwa kokwelashwa kuncike ezicini zesiguli ngasinye futhi kufanele kuxoxwe nodokotela.